Impact Lab

Impact Lab S.p.A. is a prominent player in the Italian genetics and diagnostics sector, with a focus on personalized medicine. Founded in 2015 by Vittorio Grazioli, the company aims to innovate in the world of genetics and make its benefits more accessible. A significant milestone in the company's history was the acquisition of Toma Advanced Biomedical Assays in 2019, which created the largest private genetics diagnostics hub in Italy. This union brought together Impact Lab's expertise in oncological genetics with Toma's leadership in cytogenetics, molecular biology, and prenatal diagnostics.

The group operates through a network of specialized units, including Toma Lab and Genet, providing a wide range of diagnostic services. Their offerings are based on a combination of deep pathological knowledge and the latest genetic developments. The business serves both patients and medical professionals, offering highly qualified consulting and second-opinion services. The company's business model is centered on providing these advanced diagnostic services, leveraging technological resources and a team of over 100 professionals. Their research activities benefit from an extensive database of prenatal cytogenetic diagnostics, which also supports training collaborations with universities and schools.

Keywords: genetic diagnostics, personalized medicine, oncology genetics, prenatal diagnostics, cytogenetics, molecular biology, diagnostic services, medical laboratory, biomedical assays, Italian healthcare, pathology, research and development, life sciences, healthcare innovation, genetic testing, medical consulting, clinical diagnostics